GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Valuation Rank

BNR (Burning Rock Biotech) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Burning Rock Biotech Valuation Rank Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Valuation Rank
Comparable Companies
PRE BIOQ XGN ENZ NOTV MDXH ME PMDI PRPH PRPO TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA
Traded in Other Exchanges
6BU0:Germany
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Website
https://www.brbiotech.com
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.